Outcomes and Prognosis in Adults With Mixed Cardiogenic and Vasoplegic Shock A French Multicenter Observational Study

What this Trial Is About

Mixed cardiogenic-vasoplegic shock M-CS is a serious condition combining heart dysfunction and abnormal blood vessel dilation. This observational study aims to better understand the outcomes and factors linked to this condition by examining data collected during routine care. Patients included have cardiogenic shock, with or without vasoplegia, defined by low heart output and sometimes low blood vessel resistance even with proper fluid levels and the need for vasopressors. The study collects information from patients admitted to intensive care units in three French hospitals. It includes two groups those with mixed cardiogenic-vasoplegic shock requiring norepinephrine at certain doses to maintain blood pressure, and those with cardiogenic shock without vasoplegia. No experimental treatments are given as this is a non-interventional registry. Participants data, including clinical details, treatments, and outcomes, will be analyzed for up to 90 days. Key measures include death rates, organ failure, blood pressure changes, vasopressor needs, and length of ICU and hospital stay. The study will provide valuable insights into this complex condition by reviewing routine health records over time.

Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock